Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)

Epidemiological data suggest that sex independently contributes to cardiovascular risk. Clinical trials are often hampered by the enrollment of few female patients. The Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET) and the parallel Telmisartan Randomize...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) Vol. 126; no. 8; p. 934
Main Authors: Kappert, Kai, Böhm, Michael, Schmieder, Roland, Schumacher, Helmut, Teo, Koon, Yusuf, Salim, Sleight, Peter, Unger, Thomas
Format: Journal Article
Language:English
Published: United States 21.08.2012
Subjects:
Aged
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Benzimidazoles - therapeutic use
Benzoates - therapeutic use
Female
Humans
Incidence
Male
Middle Aged
Myocardial Infarction - mortality
Myocardial Infarction - prevention & control
Ramipril - therapeutic use
Research Design
Risk Assessment - methods
Risk Factors
Sex Distribution
Sex Factors
Stroke - mortality
Stroke - prevention & control
ISSN:1524-4539, 1524-4539
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first